Enzyme replacement therapy for Gaucher disease in Australia

Area of Science:

• Biochemistry and Genetics
• Lysosomal Storage Disorders
• Pharmacology

Background:

• Gaucher disease is a sphingolipid metabolism disorder caused by beta-Glucocerebrosidase deficiency.
• Severe forms necessitate effective therapeutic interventions.
• Enzyme replacement therapy (ERT) targets the underlying enzymatic defect.

Purpose of the Study:

• To evaluate the effectiveness of a national enzyme replacement therapy (ERT) program for severe Gaucher disease.
• To assess the impact of ERT on hematological parameters and organ volumes.

Main Methods:

• Prospective analysis of patient data collected every 6 months.
• Assessed hemoglobin (Hb) and platelet (plt) concentrations.
• Measured liver and spleen volumes in 48 patients (Type 1 and Type 3B) over 6-114 months.

Main Results:

• Hemoglobin normalized in 85% of patients, with a mean increase of 20 g/L.
• Platelet counts improved significantly, reaching 75% normal levels by study end.
• Mean spleen volume reduced by 56%, and liver volume by 27% in evaluable patients.

Conclusions:

• Enzyme replacement therapy (ERT) demonstrated a range of positive effects in Gaucher disease patients.
• All patients showed improvement in hematological complications and/or reduction in organ enlargement (visceromegaly).
• Further studies will investigate ERT's effects on bone disease, growth, and quality of life.